MARKET

ALNY

ALNY

Alnylam Pharmaceuticals Inc
NASDAQ
286.98
-6.47
-2.20%
After Hours: 289.00 +2.02 +0.70% 18:16 05/15 EDT
OPEN
294.78
PREV CLOSE
293.45
HIGH
298.00
LOW
286.76
VOLUME
1.15M
TURNOVER
--
52 WEEK HIGH
495.55
52 WEEK LOW
252.79
MARKET CAP
38.32B
P/E (TTM)
68.35
1D
5D
1M
3M
1Y
5Y
1D
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As HELIOS B Data And TTR Guidance Reassure Investors
Simply Wall St · 10h ago
Alnylam’s New Hypertension Combo Study Could Reshape Its Long-Term Value
TipRanks · 1d ago
Alnylam Steps Into Obesity Drug Race With New ALN-2232 Trial
TipRanks · 1d ago
Alnylam’s New Phase 1 ALN-4915 Trial: Early Safety Data in Focus for ALNY Investors
TipRanks · 1d ago
Alnylam’s HMBeacon Trial Adds a New Growth Angle in Women’s Bleeding Disorders
TipRanks · 1d ago
PLTR, KTOS, ALNY: 3 High P/E Stocks with 40%+ Upside Potential in 2026
TipRanks · 2d ago
Alnylam announces new analyses from HELIOS-B study of vutrisiran
TipRanks · 3d ago
Alnylam Presents HELIOS-B Data At Heart Failure 2026 Supporting Vutrisiran As First-Line Treatment Across Broad ATTR-CM Populations
Benzinga · 3d ago
More
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Webull offers Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ: ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.